Candidate Compounds Covid19

Version vom 1. Juli 2020, 05:55 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

• reviews on covid drug development
• scouting ideas

• Patients on biologicals
• HMGB1, RAGE
• pre-Interleukin 6
• post-Interleukin 6
• pre-TNFalpha
• post-TNFalpha
• pre-Interleukin 17
• post-Interleukin 17
• pre-Interleukin 1
• post-Interleukin 1
• Inflammasome colchicine
• Methotrexate
• other anti-inflammatory
• NK-kappaB
• STAT 3
• JAK Janus Kinase
• Corticosteroids
• Cytokine absorbers
• Target Complement system
• Target Extracellular traps
• TGF beta
• Anticoagulant in covid19
• Antioxidants
• Stem cells
• MDSC cells
• Interferons

• other single compounds
• Retargeted single compounds
• Hydroxychloroquine
• Target ACE2, Spike protein
• Target TMPRSS2, Spike protein any other covid targed herein
• other antiviral compounds
• AV Remdesivir
• AV Lopinavir
• AV Ivermectin
• AV Arabidol
• AV Favipiravir

• Vitamin D
• Anorganic nutrients Magnesium
• Anorganic nutrients Selenium
• Anorganic nutrients Zinc
• Nutrition, general
• Exercise, Vibration

• Traditional Chinese Medicine
• Natural compounds

• Statins
• Antidiabetic compounds, any
• RSP - On RAS drugs

• Reconvalescent blood products, Passive vaccine
• Plasmapheresis

• Immunodeviation e.g. by adjuvants or other vaccinations
• Radiation therapy
• Phototherapy
• Active vaccine

-rest-

32458400 2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.
32401611 2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.
32413736 2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.
32534188 2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.
32531935 2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.
32384202 2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.
32315803 2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.
32519894 2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.
32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.
32399093 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.
32532623 2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
32401215 2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.
32468385 2020. Musings on the current state of COVID-19 modeling and reporting.
32523144 2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.
32516380 2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.
32390307 2020. Practical tips for using masks in the COVID-19 pandemic.
32358890 2020. Cutaneous side-effects of the potential COVID-19 drugs.
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.
32406749 2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.
32535509 2020. COVID-19, interferons, and depression: A commentary.
32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.
32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?
32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.
32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?
32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.
32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.
32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.
32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.
32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.
32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.
32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.
32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.
32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro

009

32535032 2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.
32435607 2020. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.
32423449 2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
32493510 2020. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
32405423 2020. Minimum costs to manufacture new treatments for COVID-19.
32405422 2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.
32405421 2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
32401274 2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.
32392282 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
32501511 2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
32530438 2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.
32459647 2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.
32384188 2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.
32533592 2020. Pharmacist's perspective on HCQ treatment of COVID-19.
32460458 2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
32401715 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
32401712 2020. Interferon beta-1b for COVID-19.
32410758 2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.
32450109 2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
32464115 2020. Caution against corticosteroid-based COVID-19 treatment.
32473680 2020. The starting line for COVID-19 vaccine development.
32450106 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
32445630 2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?
32450054 2020. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
32473139 2020. Death threats after a trial on chloroquine for COVID-19.
32518920 2020. Caution and clarity required in the use of chloroquine for COVID-19.
32501454 2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
32518419 2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
32528040 2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
32535078 2020. Vaccination strategies to combat novel corona virus SARS-CoV-2.
32535080 2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
32497632 2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
32454157 2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
32450171 2020. Coronaviruses pandemics: Can neutralizing antibodies help?
32450166 2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.
32422305 2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
32418894 2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
32478465 2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
32532461 2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.
32425245 2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.
32416415 2020. Etoposide-based therapy for severe forms of COVID-19.
32516655 2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.
32504923 2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
32485316 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
32498007 2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.
32492562 2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
32480250 2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.
32464491 2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).
32526511 2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.
32473509 2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.
32470789 2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.
32534175 2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.
32464494 2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.
32526507 2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.
32464493 2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.
32464492 2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?
32460208 2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
32425307 2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.
32425306 2020. Protective potential of Expectorants against COVID-19.
32425303 2020. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
32428811 2020. Exercise as medicine for COVID-19: An ACE in the hole?
32416408 2020. As a potential treatment of COVID-19: Montelukast.
32413699 2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
32531538 2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
32531537 2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?
32516733 2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.
32535456 2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.
32534337 2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.
32505075 2020. Fighting against frailty and sarcopenia - As well as COVID-19?
32505072 2020. COVID-19 and picotechnology: Potential opportunities.
32505069 2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.
32400020 2020. COVID-19 and implications for thiopurine use.
32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
32470350 2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.
32497535 2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
32418885 2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
32473390 2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?
32437926 2020. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
32445881 2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
32442649 2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.
32533920 2020. The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.
32404512 2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
32445440 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32445439 2020. Surgery Scheduling in a Crisis.
32433465 2020. Immunogenicity of a DNA vaccine candidate for COVID-19.
32529545 2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?
32499636 2020. COVID-19 vaccines: neutralizing antibodies and the alum advantage.
32533109 2020. Passive antibody therapy in COVID-19.
32393823 2020. BCG-induced trained immunity: can it offer protection against COVID-19?
32462282 2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
32451597 2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.
32430617 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
32350818 2020. Chloroquine-induced QTc prolongation in COVID-19 patients.
32342609 2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.
32383751 2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.
32528732 2020. Universal coronavirus vaccines: the time to start is now.
32509338 2020. Certainty of success: three critical parameters in coronavirus vaccine development.
32521760 2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.
32532069 2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?
32519174 2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?
32528623 2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?
32456404 2020. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
32431755 2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.
32451736 2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.
32454586 2020. Demand for potentially hazardous COVID-19 treatments.
32454583 2020. ICER releases pricing models for potential COVID-19 treatments.
32473310 2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
32445956 2020. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).
32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"
32442720 2020. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
32430287 2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.
32430286 2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?

32405226 2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.
32438037 2020. Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis.
32438034 2020. Does lopinavir really inhibit SARS-CoV-2?
32407959 2020. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
32502640 2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.
32470470 2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
32442437 2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
32437972 2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.
32425361 2020. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
32493609 2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?
32519302 2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
32415971 2020. Use of statins in patients with COVID-19.
32415962 2020. Reply: Use of statins in patients with COVID-19.
32437821 2020. Radiation therapy for COVID-19 pneumopathy.
32437820 2020. Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).
32413531 2020. Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable.
32522574 2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
32514354 2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.
32394513 2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
32426002 2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.
32426001 2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.
32395001 2020. Evidencia viva como respuesta a las controversias en el uso de antimalaricos en COVID-19.
32414660 2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?
32491104 2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.
32501367 2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.
32418114 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
32518317 2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
32413619 2020. beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.
32513867 2020. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
32434945 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
32404477 2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
32385228 2020. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
32467561 2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
32460839 2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
32526079 2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
32388805 2020. Low-dose radiation therapy for COVID-19 pneumopathy: what is the evidence?
32394099 2020. Low-dose radiotherapy for SARS-CoV-2 pneumonia.
32412544 2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.
32528195 2020. Broad beans (Vicia faba) and the potential to protect from COVID-19 coronavirus infection.
32528194 2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.
32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
32436445 2020. Potential specific therapies in COVID-19.
32483428 2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.
32473812 2020. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.
32418732 2020. Chloroquine and hydroxychloroquine during pregnancy: What do we know?
32457932 2020. Chloroquine, hydroxychloroquine and COVID-19.
32487513 2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
32532691 2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
32467007 2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.
32425645 2020. Use of convalescent plasma in COVID-19 patients in China.
32406985 2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
32473994 2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.
32485391 2020. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
32360423 2020. Malaria prophylaxis approach during COVID-19 pandemic.
32471655 2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.
32454984 2020. Battling COVID-19: using old weapons for a new enemy.
32376108 2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.
32387011 2020. Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.
32418794 2020. A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.
32526960 2020. Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.
32531955 2020. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.
32236815 2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.
32524253 2020. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
32530808 2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.
32531236 2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
32532094 2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
32532085 2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
32426090 2020. COVID-19, asthma, and biologic therapies: What we need to know.
32417996 2020. BCG versus COVID-19: impact on urology.
32514854 2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.